Abstract:Antibody light chain (LC) aggregation in vivo leads to the systemic deposition of Ig light chain domains in the form of either amyloid fibrils (AL-amyloidosis) or amorphous deposits, light-chain deposition disease (LCDD), in mainly cardiac or renal tissue and is a pathological condition that is often fatal. Molecular factors that may contribute to the propensity of LCs to aggregate in vivo, such as the protein primary structure or local environment, are intensive areas of study. Herein, we show that the aggregation of a human antibody kappa-(kappa-MJM) and lambda-(lambda-L155) light chain (1 mg/mL) can be accelerated in vitro when they are incubated under physiologically relevant conditions, PBS, pH 7.4 and 37 degrees C, in the presence of a panel of biologically relevant lipid-derived aldehydes, 4-hydroxynonenal (4-HNE), malondialdehyde (MDA), glyoxal (GLY), atheronal-A (KA), and atheronal-B (ALD). Thioflavin-T (ThT) and Congo Red (CR) binding assays coupled with turbidity studies reveal that this aldehyde-induced aggregation can be associated with alteration of protein secondary structure to an increased beta-sheet conformation. We observed that the nature of the conformational change is primarily dependent upon the lipidic aldehyde studied, not the protein sequence. Thus, the cholesterol 5,6-secosterols, KA and ALD, cause an amorphous-type aggregation which is ThT and CR negative for both the kappa-MJM and lambda-L155 light chains, whereas 4-HNE, MDA, and GLY induce aggregates that bind both ThT and CR. TEM analysis revealed that amyloid fibrils were formed during the 4-HNE-mediated aggregation of kappa-MJM and lambda-L155 light chains, whereas ALD-induced aggregates of these LCs where amorphous in nature. Kinetic profiles of LC aggregation reveal clear differences between the aldehydes, KA and ALD, causing a classic nucleated polymerization-type aggregation, with a lag phase (of approximately 150 h) followed by a growth phase that plateaus, whereas 4-HNE, MDA, and GLY trigger a seeded-type aggregation process that has no lag phase. In-depth studies of the 4-HNE-accelerated aggregation of kappa-MJM and lambda-L155 reveal a clear aldehyde concentration dependence and a process that can be inhibited by the naturally occurring osmolyte trimethylamine N-oxide (TMAO). Given these data, we feel our recently discovered paradigm of inflammatory aldehyde-induced protein misfolding may now extend to LC aggregation.

Annular oligomeric amyloid intermediates observed by in situ atomic force microscopy.

Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates

Investigation of the Aggregation Process of Amyloid-Β-(16-22) Peptides and the Dissolution of Intermediate Aggregates.

Computational studies of protein aggregation mediated by amyloid: Fibril elongation and secondary nucleation

Experimental Characterization of Disordered and Ordered Aggregates Populated During the Process of Amyloid Fibril Formation.

Amyloid-beta aggregates formed at polar-nonpolar interfaces differ from amyloid-beta protofibrils produced in aqueous buffers

Annular Structures As Intermediates in Fibril Formation of Alzheimer Abeta17-42.

Lipid-derived aldehydes accelerate light chain amyloid and amorphous aggregation

Atomic View of a Toxic Amyloid Small Oligomer

Gel Formation in Protein Amyloid Aggregation: A Physical Mechanism for Cytotoxicity

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

An investigation into the formation of annular aggregates of human islet amyloid polypeptide on tantalum oxide surfaces.

Characterization of the Non-Fibrillar alpha-Synuclein Oligomers

Molecular Mechanism of the Early Stage of Amyloidogenic Hexapeptides (NFGAIL) Aggregation

Amyloid Aggregation: Role of Biological Membranes and the Aggregate-Membrane System

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis

Structural, morphological, and kinetic studies of β-amyloid peptide aggregation on self-assembled monolayers.

Interrogating Amyloid Aggregation with Aggregation-Induced Emission Fluorescence Probes.

Soluble protein oligomers as emerging toxins in alzheimer's and other amyloid diseases

S100a9 Induces Aggregation-Prone Conformation in Abeta Peptides: A Combined Experimental and Simulation Study

The role of α-sheet structure in amyloidogenesis: characterization and implications